PURPOSE: To conduct a systematic literature review of the reliability, construct validity, and responsiveness of the SF-36® Health Survey (SF-36) in patients with ulcerative colitis (UC). METHODS: We performed a systematic search of electronic medical databases to identify published peer-reviewed studies which reported scores from the eight scales and/or two summary measures of the SF-36 collected from adult patients with UC. Study findings relevant to reliability, construct validity, and responsiveness were reviewed. RESULTS: Data were extracted and summarized from 43 articles meeting inclusion criteria. Convergent validity was supported by findings that 83% (197/236) of correlations between SF-36 scales and measures of disease symptoms, disease activity, and functioning exceeded the prespecified threshold (r ≥ |0.40|). Known-groups validity was supported by findings of clinically meaningful differences in SF-36 scores between subgroups of patients when classified by disease activity (i.e., active versus inactive), symptom status, and comorbidity status. Responsiveness was supported by findings of clinically meaningful changes in SF-36 scores following treatment in non-comparative trials, and by meaningfully larger improvements in SF-36 scores in treatment arms relative to controls in randomized controlled trials. The sole study of SF-36 reliability found evidence supporting internal consistency (Cronbach's α ≥ 0.70) for all SF-36 scales and test-retest reliability (intraclass correlation coefficient ≥0.70) for six of eight scales. CONCLUSIONS: Evidence from this systematic literature review indicates that the SF-36 is reliable, valid, and responsive when used with UC patients, supporting the inclusion of the SF-36 as an endpoint in clinical trials for this patient population.
PURPOSE: To conduct a systematic literature review of the reliability, construct validity, and responsiveness of the SF-36® Health Survey (SF-36) in patients with ulcerative colitis (UC). METHODS: We performed a systematic search of electronic medical databases to identify published peer-reviewed studies which reported scores from the eight scales and/or two summary measures of the SF-36 collected from adult patients with UC. Study findings relevant to reliability, construct validity, and responsiveness were reviewed. RESULTS: Data were extracted and summarized from 43 articles meeting inclusion criteria. Convergent validity was supported by findings that 83% (197/236) of correlations between SF-36 scales and measures of disease symptoms, disease activity, and functioning exceeded the prespecified threshold (r ≥ |0.40|). Known-groups validity was supported by findings of clinically meaningful differences in SF-36 scores between subgroups of patients when classified by disease activity (i.e., active versus inactive), symptom status, and comorbidity status. Responsiveness was supported by findings of clinically meaningful changes in SF-36 scores following treatment in non-comparative trials, and by meaningfully larger improvements in SF-36 scores in treatment arms relative to controls in randomized controlled trials. The sole study of SF-36 reliability found evidence supporting internal consistency (Cronbach's α ≥ 0.70) for all SF-36 scales and test-retest reliability (intraclass correlation coefficient ≥0.70) for six of eight scales. CONCLUSIONS: Evidence from this systematic literature review indicates that the SF-36 is reliable, valid, and responsive when used with UC patients, supporting the inclusion of the SF-36 as an endpoint in clinical trials for this patient population.
Authors: J E Ware; M Kosinski; B Gandek; N K Aaronson; G Apolone; P Bech; J Brazier; M Bullinger; S Kaasa; A Leplège; L Prieto; M Sullivan Journal: J Clin Epidemiol Date: 1998-11 Impact factor: 6.437
Authors: Henrik Hjortswang; Gunnar Järnerot; Bengt Curman; Hanna Sandberg-Gertzén; Curt Tysk; Björn Blomberg; Sven Almer; Magnus Ström Journal: Scand J Gastroenterol Date: 2006-10 Impact factor: 2.423
Authors: Vibeke Strand; Maarten Boers; Leanne Idzerda; John R Kirwan; Tore K Kvien; Peter S Tugwell; Maxime Dougados Journal: J Rheumatol Date: 2011-08 Impact factor: 4.666
Authors: Julián Panés; Chinyu Su; Andrew G Bushmakin; Joseph C Cappelleri; Carla Mamolo; Paul Healey Journal: BMC Gastroenterol Date: 2015-02-05 Impact factor: 3.067
Authors: B Jharap; W J Sandborn; W Reinisch; G D'Haens; A M Robinson; W Wang; B Huang; A Lazar; R B Thakkar; J-F Colombel Journal: Aliment Pharmacol Ther Date: 2015-09-03 Impact factor: 8.171
Authors: Edward Mezones-Holguin; Rocio Violeta Gamboa-Cardenas; Gadwyn Sanchez-Felix; José Chávez-Corrales; Luis Miguel Helguero-Santin; Luis Max Laban Seminario; Paula Alejandra Burela-Prado; Maribel Marilu Castro-Reyes; Fabian Fiestas Journal: Front Pharmacol Date: 2019-11-15 Impact factor: 5.810